Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Verrica Pharmaceuticals Inc shares valued at $69,647 were sold by Hayes Christopher G. on Aug 26 ’24. At $2.66 per share, Hayes Christopher G. sold 26,183 shares. The insider’s holdings dropped to 115,303 shares worth approximately $0.17 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Hayes Christopher G. sold 9,530 shares, netting a total of over 23,444 in proceeds. Following the sale of shares at $2.46 each, the insider now holds 105,773 shares.
Before that, Goldenberg Gary had sold 9,888 shares from its account. In a trade valued at $26,302, the Chief Medical Officer traded Verrica Pharmaceuticals Inc shares for $2.66 each. Upon closing the transaction, the insider’s holdings decreased to 9,888 shares, worth approximately $0.14 million.
As published in a research note from Needham on July 25, 2023, Verrica Pharmaceuticals Inc [VRCA] has been rated up from a Hold to a Buy and the price target has been revised to $10. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of February 13, 2023, RBC Capital Mkts has increased its “Sector perform” rating to a “an Outperform” for VRCA. Earlier on May 25, 2022, RBC Capital Mkts downgraded its rating. Their new recommendation was “a Sector perform” for VRCA stock which previously was a “an Outperform”.
Analyzing VRCA Stock Performance
During the last five days, there has been a drop of approximately -13.69%. Over the course of the year, Verrica Pharmaceuticals Inc shares have dropped approximately -80.19%. Shares of the company reached a 52-week high of $11.4100 on 05/14/24 and a 52-week low of $1.0404 on 10/02/24. A 50-day SMA is recorded $3.1998, while a 200-day SMA reached $5.8552. Nevertheless, trading volume fell to 11.11 million shares from 1.5 million shares the previous day.
Support And Resistance Levels for Verrica Pharmaceuticals Inc (VRCA)
According to the 24-hour chart, there is a support level at 1.1734, which, if violated, would cause prices to drop to 0.8967. In the upper region, resistance lies at 1.6533. The next price resistance is at 1.8565. RSI (Relative Strength Index) is 31.46 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.3457, which suggests the price will decrease in the coming days. Percent R is at 57.87%, indicating low price movement. Stochastics %K at buying indicates that the stock is to be held.
